Table 2. Association between clinical parameters and disease-free survival.

Parameters	Category	No. of patients	Disease-free survival (months)		P (Log Rank)
			Mean	95% CI
HURP expression	Negative	78	21.9	18.9–24.7	0.023
	Positive	19	14.1	10.2–18.1
Treatment	RFA	79	20.2	17.4–23.1	0.770
	Surgical	18	19.4	14.7–24.3
Sex	Female	35	21.1	16.7–25.4	0.772
	Male	62	19.4	16.5–22.3
Age	<65 years	45	22.6	18.9–26.3	0.105
	≥65 years	52	17.1	14.2–20.0
HBsAg	Negative	48	17.9	14.8–21.1	0.353
	Positive	49	21.5	17.9–25.0
Anti-HCV	Negative	55	20.3	16.8–23.8	0.979
	Positive	42	18.9	15.6–22.2
Alcoholism	No	78	20.8	17.8–23.8	0.606
	Yes	19	17.9	13.7–22.1
Cirrhosis	No	10	19.4	15.2–23.6	0.910
	Yes	87	20.4	17.7–23.3
Cytological grading	<3	67	22.6	19.7–25.7	0.008
	≥3	30	14.7	11.1–18.3
Tumor number	Solitary	73	21.1	18.1–24.0	0.342
	>1	24	17.0	12.8–21.3
Tumor size (diameter)	<3 cm	61	20.6	17.5–23.8	0.823
	≥3 cm	36	18.8	14.8–22.7
Ascites	Absence	86	20.0	17.2–22.7	0.435
	Presence	11	21.9	16.3–27.4
Alpha-fetoprotein	<35 ng/mL	69	22.0	19.0–25.1	0.039
	≥35 ng/mL	28	15.2	11.4–18.9
Albumin	<4 g/dL	55	19.8	16.2–23.4	0.578
	≥4 g/dL	42	20.5	17.2–23.8
Bilirubin	<1.3 mg/dL	73	21.3	18.7–23.9	0.010
	≥1.3 mg/dL	24	15.1	10.0–20.3
Prothrombin time	<12 sec	35	19.8	16.5–23.2	0.902
	≥12 sec	62	20.8	17.3–24.2
Creatinine	<1.0 mg/dL	48	21.7	18.1–25.4	0.391
	≥1.0 mg/dL	49	18.7	15.5–21.9
AST	<50 U/L	59	23.5	20.3–26.8	0.003
	≥50 U/L	38	15.2	11.7–18.8
ALT	<35 U/L	43	25.3	21.5–29.0	0.005
	≥35 U/L	54	16.5	13.7–19.4